Linden Thomas Advisory Services LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 11.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,968 shares of the life sciences company’s stock after purchasing an additional 419 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Illumina were worth $923,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the stock. Mizuho Securities Co. Ltd. lifted its holdings in shares of Illumina by 317.6% during the first quarter. Mizuho Securities Co. Ltd. now owns 710 shares of the life sciences company’s stock valued at $165,000 after purchasing an additional 540 shares during the last quarter. Asset Management One Co. Ltd. lifted its holdings in shares of Illumina by 2.3% during the first quarter. Asset Management One Co. Ltd. now owns 89,636 shares of the life sciences company’s stock valued at $20,845,000 after purchasing an additional 1,991 shares during the last quarter. Verdence Capital Advisors LLC purchased a new stake in shares of Illumina during the first quarter valued at $712,000. Windward Capital Management Co. CA lifted its holdings in shares of Illumina by 1.8% during the first quarter. Windward Capital Management Co. CA now owns 19,213 shares of the life sciences company’s stock valued at $8,890,000 after purchasing an additional 334 shares during the last quarter. Finally, Legal Advantage Investments Inc. lifted its holdings in shares of Illumina by 336.3% during the first quarter. Legal Advantage Investments Inc. now owns 4,930 shares of the life sciences company’s stock valued at $1,146,000 after purchasing an additional 3,800 shares during the last quarter. 88.66% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on ILMN shares. StockNews.com started coverage on Illumina in a research note on Thursday, May 18th. They issued a “hold” rating for the company. Robert W. Baird increased their price objective on Illumina from $224.00 to $229.00 in a research note on Wednesday, April 26th. Stifel Nicolaus increased their price objective on Illumina from $235.00 to $265.00 in a research note on Wednesday, April 26th. Finally, Royal Bank of Canada increased their price objective on Illumina from $300.00 to $337.00 and gave the stock an “outperform” rating in a research note on Friday, April 14th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average target price of $253.70.
Illumina Trading Up 0.5 %
Illumina (NASDAQ:ILMN – Free Report) last issued its quarterly earnings data on Tuesday, April 25th. The life sciences company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a positive return on equity of 2.26% and a negative net margin of 100.92%. The firm’s revenue for the quarter was down 11.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.07 EPS. On average, analysts forecast that Illumina, Inc. will post 1.4 earnings per share for the current fiscal year.
Insider Activity
In other news, SVP Susan H. Tousi sold 500 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $200.00, for a total transaction of $100,000.00. Following the transaction, the senior vice president now owns 46,522 shares of the company’s stock, valued at approximately $9,304,400. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.13% of the stock is currently owned by insiders.
Illumina Profile
Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
- Five stocks we like better than Illumina
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
